1. Pink Sheet
  2. >>Advanced Technologies

US FDA Opens OTP Director Search Again

 
• By Derrick Gingery

The new job notice offers a top salary, but also invites questions about the candidate pool attracted by the original solicitation.

leadership search
OTP director is one of many senior leadership openings in the CBER office that handles cell and gene therapies. • Source: Shutterstock

The search for the inaugural director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products is open again, this time with an increased salary range and telework opportunities that could attract more candidates.

The Office of Therapeutic Products, formerly the Office of Tissues and Advanced Therapies (OTAT), handles cell and gene therapy applications...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

More from Advanced Technologies

US FDA’s CoGenT Pilot At Risk? Project Orbis Success May Not Save Cell/Gene Therapy Initiative

 
• By Bridget Silverman

Despite following the path of the popular Project Orbis, the cell and gene therapy international collaborative review pilot is being reconsidered by the FDA's new management.

BIO Notebook: PRVs Need To Be A Priority, IPO Window Shut And Focusing On Gene Therapy Safety

 
• By Mandy Jackson and Sarah Karlin-Smith

Highlights from day one of the BIO convention include advice for firms hoping to go public, a call for companies to push the US Congress on rare disease priority review vouchers, and updates on next-generation gene therapies.

EU Decision Time For Madrigal’s MASH Drug Resmetirom And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.